Opendata, web and dolomites

Mofina

Mobile Filovirus Nucleic Acid Test – Sofia ref.: 115848

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Mofina project word cloud

Explore the words cloud of the Mofina project. It provides you a very rough idea of what is the project "Mofina" about.

inmi    nucleic    rt    expanded    alere    filovirus    prototypic    proposing    cartridges    acid    time    workflow    simultaneously    complete    safe    sampling    storage    utilize    kit    nat    detection    advantage    detect    screening    reg    material    technologies    integration    filo    rna    realstar    validation    mark    system    pan    hiv    ready    format    platform    min    marburgvirus    safely    trade    point    ebola    alone    simplify    until    operator    instrumentation    altona    cartridge    combining    verification    disposable    assay    bnitm    20    instrument    additional    species    stand    reducing    ce    2015    manufactured    genera    april    poc    starts    purpose    laboratory    mobile    risk    fast    infection    march    capillary    preparation    virus    45    human    molecular    care    acute    sensitive    blood    commercial    sites    rapid    central    pcr    venous    deg    ivd    infrastructure    designed    samples    proven    diagnostics    logistics   

Project "Mofina" data sheet

The following table provides information about the project.

Coordinator
Department of Health 

Organization address
address: Quarry House, Quarry Hill
city: Leeds
postcode: LS2 7UE
website: www.dh.gov.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Project website https://www.imi.europa.eu/projects-results/project-factsheets/mofina
 Total cost 4˙398˙252 €
 EC max contribution 1˙162˙622 € (26%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2014-02-single-stage
 Funding Scheme IMI2-RIA
 Starting year 2015
 Duration (year-month-day) from 2015-02-01   to  2017-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    Department of Health UK (Leeds) coordinator 332˙460.00
2    ALTONA DIAGNOSTICS GMBH DE (HAMBURG) participant 394˙178.00
3    BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN DE (HAMBURG) participant 217˙992.00
4    ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE LAZZARO SPALLANZANI-ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO IT (ROMA) participant 217˙992.00
5    ALERE TECHNOLOGIES GMBH DE (JENA) participant 0.00
6    FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS CH (GENEVE) participant 0.00

Map

 Project objective

We are proposing to develop a molecular assay for the safe, rapid, specific and sensitive detection of Ebola Virus Infection in capillary (or venous) blood samples combining ALTONA’s Pan-filo screening IVD test with the existing Alere™ q point of care molecular diagnostics platform. The purpose of this project is to utilize existing and proven PCR assay(s) designed for laboratory use and to take advantage of the Alere™ q point of care molecular instrument and cartridge design to simplify Ebola testing so that molecular testing can be expanded to sites beyond which high end laboratory infrastructure is not available while simultaneously greatly reducing infection risk for the test operator. The project aims for the fast development of a point of care Nucleic Acid Test (POC-NAT) system for filovirus specific RNA, from human sample material, especially from blood samples. The POC-NAT system will have the following features: 1. Field proven stand alone, mobile and easy to use instrumentation 2. ready to use cartridge, safely disposable nucleic acid test format with integrated sample preparation 3. assay for specific detection of RNA of all known species from the virus genera Ebola- and Marburgvirus . 4. process duration from sampling to result less than 45 min 5. no additional equipment and no logistics and storage at -20°C needed The POC-NAT is based on two already existing technologies: The instrument platform “Alere™q complete” developed and manufactured by Alere , an instrument for POC diagnostics recently used p.e. for Alere´s HIV-1/2 Detect cartridges, and altona Diagnostics´ RealStar® Filovirus RT-PCR kit 1.0, a commercial central laboratory real-time PCR test. The project partner aim for having the integration of platform and assay as a prototypic system completed until end of March 2015. The verification and validation of the workflow starts April 2015 at altona Diagnostics, BNITM and INMI. The aim of this project phase is to finally CE IVD mark the test system

 Publications

year authors and title journal last update
List of publications.
2015 Chris A Whitehouse, Sina Bavari, Mark D Perkins
United States FDA’s emergency use authorization of Ebola virus diagnostics: current impact and lessons for the future
published pages: 1231-1235, ISSN: 1473-7159, DOI: 10.1586/14737159.2015.1077117
Expert Review of Molecular Diagnostics 15/10 2019-07-24
2015 Mark D Perkins, Mark Kessel
What Ebola tells us about outbreak diagnostic readiness
published pages: 464-469, ISSN: 1087-0156, DOI: 10.1038/nbt.3215
Nature Biotechnology 33/5 2019-07-24

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MOFINA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MOFINA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More  

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

VITAL (2019)

Vaccines and Infectious Diseases in the Ageing PopuLation

Read More